Does trading below fair value make a stock a buy?

Not necessarily, as there may be fundamental reasons for the decline. However, it could indicate undervaluation if fundamentals are strong.

Does the report recommend buying either stock?

No, the report does not provide a buy or sell recommendation; it analyzes the technical signals and encourages investors to study the fundamentals.

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Q: What is the main difference between the reasons for Pfizer's and Gilead's declines?

Pfizer is suffering from declining COVID-19 product revenues, while Gilead faces challenges in its antiviral drug pipeline.

Both Pfizer and Gilead Sciences flashed similar technical warnings while trading below analyst fair value, but the reasons behind each selloff differ. This analysis explores whether a contrarian opportunity exists.

July 15, 2026

2 min read

Source: 24/7 Wall St.

According to a report from 24/7 Wall St., both Pfizer (PFE) and Gilead Sciences (GILD) have shown similar ominous technical warnings while trading below analyst fair value. However, the reasons behind each selloff tell very different stories about which one actually deserves a second look.

Recommendation Change

The report does not explicitly mention any analyst rating change, but the fact that both stocks are trading below fair value suggests they may be undervalued.

Analyst's Rationale

The source suggests that the similar technical warnings could mask a contrarian opportunity, especially if the selloff is overdone. However, the fundamental differences between the two companies determine which one is worth considering.

Context

Pfizer's stock is trading at low levels due to declining COVID-19 product revenues, while Gilead faces challenges in its antiviral drug pipeline. Nevertheless, both have strong fundamentals that may attract long-term investors.

What to Conclude

Despite similar technical signals, investors need to analyze the underlying reasons behind each stock's decline to determine if a true contrarian opportunity exists. It is advisable to wait for more clarity on each company's growth prospects.

Frequently Asked Questions

Both stocks showed similar technical warnings indicating weak upward momentum, but the report did not specify the exact technical indicator.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.